Inflammatory and immune markers in oral cancer patients (None)

Inflammatory and immune markers in oral cancer patients encompass a diverse array of cytokines, chemokines, and cellular profiles that characterize the tumor microenvironment and systemic response to malignancy. Key markers such as Interleukin-6 (IL-6), Interleukin-8 (IL-8), and Tumor Necrosis Factor-alpha (TNF-alpha) are frequently elevated in the saliva and serum of patients with oral squamous cell carcinoma (OSCC), reflecting a state of chronic inflammation that facilitates tumor progression and angiogenesis (Punyani & Sathawane, 2013, J Oral Maxillofac Pathol). Additionally, immune checkpoint proteins like Programmed death-ligand 1 (PD-L1) are often upregulated, allowing tumor cells to evade T-cell-mediated destruction (Ferris et al., 2016, N Engl J Med). Cellular indices, such as the neutrophil-to-lymphocyte ratio (NLR), serve as systemic indicators of the balance between pro-tumor inflammation and anti-tumor immunity, providing significant prognostic value (Cho et al., 2016, Oral Oncology). While this collective term does not refer to a single molecular entity, individual markers within this group are the focus of targeted therapies, including monoclonal antibodies that inhibit checkpoint signaling or neutralize pro-inflammatory cytokines. Understanding these markers is essential for developing personalized treatment strategies and improving early detection through non-invasive liquid biopsies.

Other names

Oral cancer inflammatory biomarkersImmune profile of oral squamous cell carcinomaSalivary inflammatory mediatorsOSCC immune markers

Inhibition of immune checkpoint pathways (e.g., PD-1/PD-L1) to enhance T-cell activity, or neutralization of pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) to suppress the tumor-promoting inflammatory microenvironment.